14th November, Adocia supports World Diabetes Day

Diabetes concerns every family

About Diabetes and World Diabetes Day

Diabetes is a global pandemic, affecting more than 425 million people worldwide in 2017, according to the International Diabetes Federation (IDF). The IDF predicts that this figure will reach 629 million in 2045.

The seriousness of the pandemic prompted the United Nations to declare November 14 as the United Nations World Diabetes Day.

Since its inception in 1991, World Diabetes Day has been a symbol of collective mobilization. this year, the theme is Diabetes concerns every family.

Its goal: to raise awareness about diabetes, its management and the means to prevent it.

 

Diabetes: we are all concerned

425 million adults (1 in 11 adults) have #diabetes – 1 in 2 remains undiagnosed

http://www.diabetesatlas.org/

1 in 2 adults with diabetes is undiagnosed (212 millions)

http://www.diabetesatlas.org/key-messages.html

1 in 6 births is affected by hyperglycaemia in pregnancy

http://www.diabetesatlas.org/key-messages.html

Over 1 million children and adolescents have type 1 diabetes

http://www.diabetesatlas.org/key-messages.html

3/4 of people with diabetes live in low- and middle-income countries

http://www.diabetesatlas.org/key-messages.html

2/3 of people with diabetes live in urban areas (279 million)

http://www.diabetesatlas.org/key-messages.html

12% of global health expenditure is spent on diabetes ($727 billion)

http://www.diabetesatlas.org/key-messages.html

In France: in 2015, 3.7 million people were taking medication for diabetes (ie 5.4% of the population).

https://www.federationdesdiabetiques.org/information/diabete/chiffres-france

1 person dies of diabetes every 6 seconds in the world, more than AIDS, tuberculosis and malaria.

https://www.federationdesdiabetiques.org/information/definition-diabete/chiffres-monde

Nearly half of all deaths due to hyperglycemia occur before the age of 70. WHO predicts that by 2030, diabetes will be the 7th leading cause of death in the world (Projections of global mortality and burden of disease from 2002 to 2030. Mathers CD, Loncar D. PLoS Med, 2006, 3(11):e442.).

http://www.who.int/fr/news-room/fact-sheets/detail/diabetes

 

Adocia innovates to advance diabetes treatment

Adocia works every day to develop more effective, more affordable treatments that could make life easier for people with diabetes.

Out of the 6 clinical-stage products developed by Adocia, 4 are dedicated to mealtime diabetes treatment. The stakes are high because chronic hyperglycemia due to excessive glucose changes after meals is associated with long-term complications of diabetes. It is estimated that 79%[1] of people living with diabetes will develop severe complications:

> BioChaperone® Lispro U100 et U200, two prandial insulins that act very quickly and for a limited time to a few hours after a meal. Such  products enable earlier control of hyperglycemia and may be dosed at the time of the meal, to enable a more accurate dosage. Additionally, ultra-rapid insulins are considered a key element to facilitate the development of fully automated insulin pumps (also called “artificial pancreas“). BC Lispro is ready to enter Phase 3 and has been tested in 9 clinical trials to date.

> BioChaperone® Pramlintide Insulin ; a powerful multi-hormonal treatment, easy-to-use and more physiological since it combines two synergetic hormones naturally co-secreted by a healthy pancreas to control glycemia, to improve long-term outcomes. Adocia recently reported positive first-in-human results (Phase1) for BC Pram Ins.

> BioChaperone® Combo is a combination of slow-acting and fast-acting insulins designed for people who are looking for a simpler way of managing their blood glucose throughout the day, without compromising on efficacy (one product, less injections). BC Combo is in Phase 2 and has been tested in 5 clinical trials to date.

> HinsBet® U100, a rapid-acting human insulin formulation, for people with type 1 and type 2 diabetes living in low- and middle-income countries. HinsBet is in Phase 2 and has been tested in 2 clinical trials to date.

> BioChaperone®  Glucagon, an aqueous formulation of human glucagon for the emergency treatment of severe hypoglycaemia for patients. Adocia recently reported positive first-in-human results (Phase1) for BC Glucagon.

 

Would you like to join the action against diabetes?

 

 

  • The Juvenile Diabetes Research Foundation funds research on type 1 diabetes, with the goal of permanently healing patients. It also supports actions to raise awareness and promote the cause of people with diabetes.

 

Or join any cause of your choice next to your home. Diabetes concerns every family!

 

To learn more about diabetes in the world

http://www.who.int/topics/diabetes_mellitus/fr/

http://www.diabetesatlas.org/

https://www.federationdesdiabetiques.org/

https://diatribe.org/

https://www.sfdiabete.org/presse/chiffres-cles

https://diabetelab.federationdesdiabetiques.org/diabete-monde/

 

 

www.adocia.com

 

[1] Hazel-Fernandez & al; Am J Manag Care. 2015